Breath

Breath Therapeutics is a biopharmaceutical company specializing in the development of advanced inhalation therapies for severe respiratory diseases. The company's lead program, L-CsA-i (liposomal cyclosporine A for inhalation), is a novel therapy designed to treat Bronchiolitis Obliterans Syndrome (BOS), a fatal orphan disease affecting lung transplant recipients. Founded as a spin-off from PARI Pharma, Breath Therapeutics utilizes proprietary drug-nebulizer combinations to optimize delivery to the peripheral airways. The company successfully advanced its lead candidate into global Phase 3 clinical trials before being acquired. In 2019, the Italian pharmaceutical group Zambon acquired Breath Therapeutics for up to €500 million to strengthen its presence in the respiratory and orphan drug markets. Breath Therapeutics continues to operate as a key component of Zambon's specialty respiratory business.